Patterns of buprenorphine/naloxone prescribing: an analysis of claims data from Massachusetts

Assessing the feasibility, usability and acceptability of the MySafeRx platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial

“…The majority of patients in need of B/N for OUD can now access a prescription regardless of their geographic location in the U.S. ( Li et al., 2016 ; Lin and Knudsen, 2019 ; Marino et al., 2019 ; Paulsen et al., 2020 ; Skolnick, 2018 ; Zoorob et al., 2018 ). Given this increase in B/N prescribing in the years leading up to the COVID-19 pandemic, and further lifting of B/N prescription restrictions due to the COVID-19 pandemic ( Uscher-Pines et al., 2020 ), it has become increasingly difficult to establish a high level of adherence monitoring for patients prescribed B/N.…”